4 terminated. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Terminated 4 |
Follow Relapsing Multiple Sclerosis: new trials by email Literature Review of Relapsing Multiple Sclerosis trials Research Report on Relapsing Multiple Sclerosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Fecal Microbial Transplantation in Relapsing Multiple Sclerosis Patients Fecal microbiota - Autoimmune Diseases, Relapsing Multiple Sclerosis | Phase 2 | Terminated | London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | 14 | 2017-08-24 | 2019-12-02 |
| Natalizumab Subcutaneous Immunogenicity and Safety Study natalizumab - Relapsing Multiple Sclerosis | Phase 2 | Terminated | Biogen | 2 | 2014-12-01 | 2024-06-03 |
| Atacicept in Multiple Sclerosis Extension Study, Phase II Atacicept 25 mg, Atacicept 75 mg, Atacicept 150 mg - Relapsing Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 74 | 2009-03-01 | 2017-03-20 |
| A Phase 2 Study of Atacicept in Subjects With Relapsing Multiple Sclerosis (ATAMS) Atacicept, Placebo matched to atacicept - Relapsing Multiple Sclerosis | Phase 2 | Terminated | EMD Serono | 255 | 2008-04-01 | 2016-05-24 |
Autoimmune Diseases (1) · Multiple Sclerosis (1)
Autoimmune Diseases of the Nervous System (1) · Demyelinating Autoimmune Diseases, CNS (1) · Demyelinating Diseases (1) · Immune System Diseases (1) · Nervous System Diseases (1)
TACI receptor-IgG Fc fragment fusion protein (2) · Fecal Microbiota Transplantation (1) · Natalizumab (1)
EMD Serono (2) · Biogen (1) · London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's (1)
Belgium (3) · Canada (3) · Australia (2) · Czechia (2) · France (2) · Germany (2) · Lebanon (2) · Lithuania (2) · Netherlands (2) · Russia (2) · Spain (2) · Sweden (2) · Switzerland (2) · Ukraine (2) · United Kingdom (2)
Daniel Mikol, MD, PhD (1) · Marcelo Kremenchutzky, MD, FRCP (1)
2014 (1)